Abstract 1510TiP
Background
Osimertinib (Osi) is the standard first-line therapy for patients (pts) with advanced NSCLC harbouring common Epidermal Growth Factor Receptor (EGFR) mutations. Not all pts achieve durable benefit during treatment developing early resistance. Increasing evidence suggest a potential implication of Tumor Protein 53 (TP53) in the biological mechanisms underlying resistance to Tyrosine Kinase Inhibitors (TKIs). Our previous study on EGFR+ advanced NSCLC pts receiving first-line gefitinib showed that additional coexisting mutations (ACM) significantly decrease the efficacy of TKIs and, among them, TP53 mutations were exclusively documented in poor/intermediate responders than in good, supporting the potential role of this gene in influencing the response to anti-EGFR agents. These data highlight the need of applying more informative and comprehensive techniques for molecular analysis and treatment monitoring to implement the prediction of the awaited TKIs efficacy, identify pts who will not benefit from TKIs and ideally build for them a rational polytherapy strategy.
Trial design
TEMPLE-2 (NCT05785208) is a prospective, biomarker-driven, multicenter, open-label, clinical trial to evaluate the efficacy of Osi in treatment-nai¨ve patients affected by EGFR+ NSCLC according to TP53 mutational status. Inclusion criteria are: age >18 years, histologically confirmed diagnosis of EGFR+ NSCLC, available tumor tissue sample. The study consists of a screening phase to assess eligibility; a treatment phase in which pts will receive Osi at standard dose of 80 mg daily and a follow-up phase to monitor survival status and subsequent therapies. A population of 122 enrolled pts is expected, 61 TP51-wilde type and 61 TP-53 mutant. Primary endpoint is Progression Free Survival (PFS) according to TP53 mutational status; key secondary endpoints are Overall Survival (OS), Overall Response Rate (ORR), Disease Control Rate (DCR), Time to Central Nervous System (CNS) Progression, CNS ORR and Safety. Concomitant genomic alterations will be evaluated in tissue and blood at baseline and progression; ctDNA will be monitored during treatment. Enrollment is ongoing.
Clinical trial identification
NCT05785208.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Funding
AstraZeneca.
Disclosure
E. Bria: Financial Interests, Personal, Advisory Board: AZ, Roche, BMS, MSD, Eli Lilly, Amgen, Pfizer, Novartis; Financial Interests, Personal, Invited Speaker: AZ, Roche, BMS, MSD, Eli Lilly, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: AZ, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21